Monitoring of Rivaroxaban Therapy in Hypercoagulable Dogs.

ABSTRACT:

Background

Measurement of rivaroxaban efficacy using the rivaroxaban-specific anti-Xa assay (raXa) can be used for monitoring in veterinary medicine. Detection of rivaroxaban efficacy using other hemostatic tests would make monitoring timelier and more accessible.

Objectives

Compare results of raXa with prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, tissue factor (TF) and kaolin-activated thromboelastography (TEG), and thrombin generation (TG) in hypercoagulable dogs.

Animals

Twelve client-owned dogs, diagnosed with hypercoagulability or thromboembolic disease, and prescribed rivaroxaban, were recruited from a tertiary referral hospital from 2020 to 2022.

Methods

Prospective clinical trial. Jugular vein blood samp

SUBMITTER: Phillips EM 

PROVIDER: S-EPMC11836667 | biostudies-literature | 2025 Mar-Apr

REPOSITORIES: biostudies-literature